Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)

Journal of Medicinal Chemistry

Volumn 56, Issue 18, 2013, Pages 7212-7221

  Liu, Wei ^a,b,c   Yu, Bing ^a,b   Xu, Gang ^a   Xu, Wei Ren ^a,b   Loh, Mignon L ^d   Tang, Li Da ^b   Qu, Cheng Kui ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOTANSHINONE; INTERLEUKIN 3; JANUS KINASE 2; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5 PROTEIN; TANSHINONE I; TANSHINONE IIA;

AMINO ACID COMPOSITION; ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MOLECULAR DOCKING; MOUSE; NONHUMAN; NOONAN SYNDROME; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CATALYTIC DOMAIN; CELL LINE, TUMOR; COMPUTER-AIDED DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MICE; MODELS, MOLECULAR; MUTATION; PHENANTHRENES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84884996061     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400474r     Document Type: Article

References (42)

1. Loh, M. L.; Vattikuti, S.; Schubbert, S.; Reynolds, M. G.; Carlson, E.; Lieuw, K. H.; Cheng, J. W.; Lee, C. M.; Stokoe, D.; Bonifas, J. M.; Curtiss, N. P.; Gotlib, J.; Meshinchi, S.; Le Beau, M. M.; Emanuel, P. D.; Shannon, K. M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis Blood 2004, 103, 2325-2331 (Pubitemid 38326253)
2. Loh, M. L.; Reynolds, M. G.; Vattikuti, S.; Gerbing, R. B.; Alonzo, T. A.; Carlson, E.; Cheng, J. W.; Lee, C. M.; Lange, B. J.; Meshinchi, S. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group Leukemia 2004, 18, 1831-1834 (Pubitemid 39530013)
3. Tartaglia, M.; Martinelli, S.; Cazzaniga, G.; Cordeddu, V.; Iavarone, I.; Spinelli, M.; Palmi, C.; Carta, C.; Pession, A.; Arico, M.; Masera, G.; Basso, G.; Sorcini, M.; Gelb, B. D.; Biondi, A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia Blood 2004, 104, 307-313 (Pubitemid 38900008)
4. Tartaglia, M.; Mehler, E. L.; Goldberg, R.; Zampino, G.; Brunner, H. G.; Kremer, H.; van der Burgt, I.; Crosby, A. H.; Ion, A.; Jeffery, S.; Kalidas, K.; Patton, M. A.; Kucherlapati, R. S.; Gelb, B. D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nat. Genet. 2001, 29, 465-468 (Pubitemid 34326699)
5. Tartaglia, M.; Niemeyer, C. M.; Fragale, A.; Song, X.; Buechner, J.; Jung, A.; Hahlen, K.; Hasle, H.; Licht, J. D.; Gelb, B. D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia Nat. Genet. 2003, 34, 148-150 (Pubitemid 36666923)
6. Bentires-Alj, M.; Paez, J. G.; David, F. S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J. M.; Richardson, A.; Bardelli, A.; Sugarbaker, D. J.; Richards, W. G.; Du, J.; Girard, L.; Minna, J. D.; Loh, M. L.; Fisher, D. E.; Velculescu, V. E.; Vogelstein, B.; Meyerson, M.; Sellers, W. R.; Neel, B. G. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia Cancer Res. 2004, 64, 8816-8820 (Pubitemid 39665483)
7. Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors Oncogene 2008, 27, 3508-3515 (Pubitemid 351793798)
8. Loh, M. L.; Sakai, D. S.; Flotho, C.; Kang, M.; Fliegauf, M.; Archambeault, S.; Mullighan, C. G.; Chen, L.; Bergstraesser, E.; Bueso-Ramos, C. E.; Emanuel, P. D.; Hasle, H.; Issa, J. P.; van den Heuvel-Eibrink, M. M.; Locatelli, F.; Stary, J.; Trebo, M.; Wlodarski, M.; Zecca, M.; Shannon, K. M.; Niemeyer, C. M. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia Blood 2009, 114, 1859-1863
9. Muramatsu, H.; Makishima, H.; Jankowska, A. M.; Cazzolli, H.; O'Keefe, C.; Yoshida, N.; Xu, Y.; Nishio, N.; Hama, A.; Yagasaki, H.; Takahashi, Y.; Kato, K.; Manabe, A.; Kojima, S.; Maciejewski, J. P. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia Blood 2010, 115, 1969-1975
10. Araki, T.; Mohi, M. G.; Ismat, F. A.; Bronson, R. T.; Williams, I. R.; Kutok, J. L.; Yang, W.; Pao, L. I.; Gilliland, D. G.; Epstein, J. A.; Neel, B. G. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation Nat. Med. 2004, 10, 849-857 (Pubitemid 39070859)
11. Chan, G.; Kalaitzidis, D.; Usenko, T.; Kutok, J. L.; Yang, W.; Mohi, M. G.; Neel, B. G. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis Blood 2009, 113, 4414-4424
12. Xu, D.; Liu, X.; Yu, W. M.; Meyerson, H. J.; Guo, C.; Gerson, S. L.; Qu, C. K. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells J. Exp. Med. 2011, 208, 1977-1988
13. Barford, D.; Neel, B. G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2 Structure 1998, 6, 249-254 (Pubitemid 28159307)
14. Eck, M. J.; Pluskey, S.; Trub, T.; Harrison, S. C.; Shoelson, S. E. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 Nature 1996, 379, 277-280
15. Hof, P.; Pluskey, S.; Dhe-Paganon, S.; Eck, M. J.; Shoelson, S. E. Crystal structure of the tyrosine phosphatase SHP-2 Cell 1998, 92, 441-450 (Pubitemid 28101108)
16. Keilhack, H.; David, F. S.; McGregor, M.; Cantley, L. C.; Neel, B. G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes J. Biol. Chem. 2005, 280, 30984-30993 (Pubitemid 41291831)
17. Xu, D.; Qu, C. K. Protein tyrosine phosphatases in the JAK/STAT pathway Front. Biosci. 2008, 13, 4925-4932 (Pubitemid 351599646)
18. Chan, G.; Kalaitzidis, D.; Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer Cancer Metastasis Rev. 2008, 27, 179-192
19. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease Nat. Rev. Mol. Cell Biol. 2006, 7, 833-846 (Pubitemid 44627477)
20. Neel, B. G.; Gu, H.; Pao, L. The "Shp"ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem. Sci. 2003, 28, 284-293 (Pubitemid 36776291)
21. Dance, M.; Montagner, A.; Salles, J. P.; Yart, A.; Raynal, P. The molecular functions of Shp2 in the Ras/mitogen-activated protein kinase (ERK1/2) pathway Cell. Signalling 2008, 20, 453-459
22. Newman, D. J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 2008, 51, 2589-2599 (Pubitemid 351620778)
23. Tartaglia, M.; Martinelli, S.; Stella, L.; Bocchinfuso, G.; Flex, E.; Cordeddu, V.; Zampino, G.; Burgt, I.; Palleschi, A.; Petrucci, T. C.; Sorcini, M.; Schoch, C.; Foa, R.; Emanuel, P. D.; Gelb, B. D. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease Am. J. Hum. Genet. 2006, 78, 279-290 (Pubitemid 43157567)
24. Yu, W. M.; Hawley, T. S.; Hawley, R. G.; Qu, C. K. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling Oncogene 2003, 22, 5995-6004 (Pubitemid 37175877)
25. Emanuel, P. D.; Bates, L. J.; Castleberry, R. P.; Gualtieri, R. J.; Zuckerman, K. S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors Blood 1991, 77, 925-929
26. Lyubynska, N.; Gorman, M. F.; Lauchle, J. O.; Hong, W. X.; Akutagawa, J. K.; Shannon, K.; Braun, B. S. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice Sci. Transl. Med. 2011, 3, 76ra27
27. Chan, R. J.; Leedy, M. B.; Munugalavadla, V.; Voorhorst, C. S.; Li, Y.; Yu, M.; Kapur, R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor Blood 2005, 105, 3737-3742 (Pubitemid 40628224)
28. Nishida, K.; Hirano, T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors Cancer Sci. 2003, 94, 1029-1033 (Pubitemid 38035515)
29. Gu, H.; Neel, B. G. The "Gab" in signal transduction Trends Cell Biol. 2003, 13, 122-130
30. Schubbert, S.; Lieuw, K.; Rowe, S. L.; Lee, C. M.; Li, X.; Loh, M. L.; Clapp, D. W.; Shannon, K. M. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells Blood 2005, 106, 311-317 (Pubitemid 40967207)
31. Yu, W. M.; Daino, H.; Chen, J.; Bunting, K. D.; Qu, C. K. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling J. Biol. Chem. 2006, 281, 5426-5434 (Pubitemid 43847637)
32. Zhou, L. M.; Zuo, Z.; Chow, M. S. S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use J. Clin. Pharmacol. 2005, 45, 1345-1359 (Pubitemid 41643896)
33. Lu, Y.; Foo, L. Y. Polyphenolics of Salvia-a review Phytochemistry 2002, 59, 117-140 (Pubitemid 34123576)
34. Stickel, F.; Brinkhaus, B.; Krahmer, N.; Seitz, H. K.; Hahn, E. G.; Schuppan, D. Antifibrotic properties of botanicals in chronic liver disease Hepatogastroenterology 2002, 49, 1102-1108 (Pubitemid 34809798)
35. Wojcikowski, K.; Johnson, D. W.; Gobe, G. Herbs or natural substances as complementary therapies for chronic kidney disease: ideas for future studies J. Lab. Clin. Med. 2006, 147, 160-166
36. Yu, X. Y.; Lin, S. G.; Chen, X.; Zhou, Z. W.; Liang, J.; Duan, W.; Chowbay, B.; Wen, J. Y.; Chan, E.; Cao, J.; Li, C. G.; Zhou, S. F. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier Curr. Drug Metab. 2007, 8, 365-377 (Pubitemid 46780064)
37. Chen, W.; Lu, Y.; Chen, G.; Huang, S. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer Anti-Cancer Agents Med. Chem. 2013, 13, 979-987
38. Shin, D. S.; Kim, H. N.; Shin, K. D.; Yoon, Y. J.; Kim, S. J.; Han, D. C.; Kwon, B. M. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells Cancer Res. 2009, 69, 193-202
39. Chen, W.; Luo, Y.; Liu, L.; Zhou, H.; Xu, B.; Han, X.; Shen, T.; Liu, Z.; Lu, Y.; Huang, S. Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation Cancer Prev. Res. 2010, 3, 1015-1025
40. Chen, W.; Liu, L.; Luo, Y.; Odaka, Y.; Awate, S.; Zhou, H.; Shen, T.; Zheng, S.; Lu, Y.; Huang, S. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells Cancer Prev. Res. 2012, 5, 778-787
41. Zhang, X.; He, Y.; Liu, S.; Yu, Z.; Jiang, Z. X.; Yang, Z.; Dong, Y.; Nabinger, S. C.; Wu, L.; Gunawan, A. M.; Wang, L.; Chan, R. J.; Zhang, Z. Y. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) J. Med. Chem. 2010, 53, 2482-2493
42. Yu, W. M.; Guvench, O.; Mackerell, A. D.; Qu, C. K. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay J. Med. Chem. 2008, 51, 7396-7404